The COVID Advisor

Social media platforms lit up minutes after the FDA announced its authorization of the updated Novavax COVID-19 vaccine right before Labor Day weekend. It was the last of three vaccines authorized for 2024-2025, and the news was greeted with glee by many. “That’s great!” proclaimed one Reddit user, as others posted “Yes!!” and “Bravo!” In All About Novavax, a private Facebook group of more than 1,000 members, many reposted the FDA announcement and began to compare notes about when they expect to be able to get it. Another group that had submitted petitions to the FDA, urging the agency not to delay the Novavax authorization for this year, posted, “We did it!” and “Success!” after the announcement.   In terms of doses given, Novavax trails far behind Moderna’s and Pfizer’s COVID vaccines, placing dead last. Estimates vary, but as of Aug. 10, in the U.S., more than 400 million Pfizer doses had been given, more than 251 million Moderna, and 83,047 Novavax doses, according to  data resea

If you are confused about the recommendations made by different professional groups for the COVID-19 pandemic, you've come to the right place.  The U.S. Centers for Disease Control and Prevention (CDC) said that COVID-19 levels across the United States are currently “very high” in more than half of the states, with Omicron variant KP.3.1.1 accounting for about half of all cases; for the two-week period ending September 14, 2024 ( source ). A spokesperson for the CDC told The Epoch Times that the KP.3.1.1 “is very similar to other circulating variants in the United States, and all current lineages are descendants of JN.1, which emerged in late 2023.” Some media outlets have referred to both the KP.2 and KP.3 variants as “FLiRT,” (which stands for mutations in the virus's spike protein at positions designated "F for L" and "R for T"). Are the current treatment options still relevant? The number of options for the treatment of COVID-19 has increa

Early treatment is critical and the most important factor in managing this disease. COVID-19 is a clinical diagnosis; a confirmed antigen or PCR test is not required. Treatment should be initiated immediately after the onset of flu-like symptoms. The multiple therapies and drugs in this protocol have different mechanisms of action and work synergistically during various phases of the disease. About I-CARE Protocol The information in this document is our recommended approach to COVID-19 based on the best (and most recent) literature. It is provided as guidance to healthcare providers worldwide on the early treatment of COVID-19. Patients should always consult with their provider before starting any medical treatment. New medications may be added and/or changes made to doses of existing medications as further evidence emerges. Please be sure you are using the latest version of this protocol. Warning (anesthesia and surgery): Please notify your anesthesia team if you are using the followi